Advanced systemic mastocytosis
Not recruitingStudy on the Safety and Effectiveness of Bezuclastinib for Patients with Advanced Systemic Mastocytosis
Study on the Safety and Effectiveness of Bezuclastinib for Patients with Advanced Systemic Mastocytosis
- Disease:Advanced systemic mastocytosis
- Substances:3,4-Dimethyl-N-(2-Phenyl-1H-Pyrrolo[2,3-B]Pyridin-5-Yl)-1H-Pyrazole-5-Carboxamide
Italy- Participants:18–64 years · 65+ years
- Substances:3,4-Dimethyl-N-(2-Phenyl-1H-Pyrrolo[2,3-B]Pyridin-5-Yl)-1H-Pyrazole-5-Carboxamide
- Sponsor:Cogent Biosciences Inc.













